1Department of Endocrinology & Internal Medicine, King Fahad Central Hospital, Jizan, Saudi Arabia; 2Department of Family & Community Medicine, College of Medicine, Najran University, Najran, Saudi Arabia *Corresponding Author e-mail: awadresearch17@gmail.com تشخيص متأخر للنوع الثاين من مرض نقص إنزمي α-5-ريدوكتاس، لفتاة مراهقة مصابة بانقطاع الطمث األويل تقرير حالة عبد الرحمن اأحمد حمادي، عايل عمر يحيى، عو�س حممد القحطاين abstract: Deficiency of the 5-α-reductase enzyme has been found to affect male sexual development. We report an 18-year-old patient who was referred to an endocrinology clinic in Jizan, Saudi Arabia, in April 2014 with primary amenorrhoea, virilisation and a lack of secondary sex characteristics. As female external genitalia were present at birth, she had been raised as a female. Magnetic resonance imaging revealed no uterine or ovarian tissue in the pelvis and the presence of a scrotal sac. She was diagnosed with 5-α-reductase type 2 deficiency, a 46,XY disorder of sexual development. Typically, affected males have pseudovaginal perineoscrotal hypospadias and ambiguous genitalia at birth. Individuals who have been raised as female manifest characteristics of virilisation at puberty, including deepening of the vocal tone, phallus enlargement, scrotal hyperpigmentation and increased muscle mass. Keywords: 46, XY Disorders of Sex Development; Testosterone 5-alpha-Reductase; Dihydrotestosterone; Hypospadias; Puberty; Case Report; Saudi Arabia. مت عاما 18 العمر من تبلغ مري�سة عن حالة �سجلنا للذكور. اجلن�سي التطور على يوؤثر α-5-ريدوكتا�س اإنزمي نق�س اأن وجد امللخ�ص: اإحالتها اإىل عيادة الغدد ال�سماء يف جازان باململكة العربية ال�سعودية، يف اأبريل 2014 مع انقطاع الطمث االأويل، والرتجل، وعدم وجود يكت�سف مل كاأنثى. ن�ساأت فقد الوالدة، عند لها حا�رشة كانت لالإناث اخلارجية التنا�سلية االأع�ساء اأن ومبا ثانوية. جن�سية خ�سائ�س الت�سوير بالرنني املغناطي�سي اأي ن�سيج للرحم اأو املبي�س يف احلو�س، وتبني وجود كي�س ال�سفن. ومت ت�سخي�سها باأنها م�سابة بالنوع الثاين من مر�س نق�س اإنزمي α-5-ريدوكتا�س، XY،46 وهو ا�سطراب يف النمو اجلن�سي. عادة ما يكون لدى الذكور املت�رشرين مهبل كاذب �سن يف الرتجل �سفات كاإناث تن�سئتهم متت الذين االأفراد ويظهر وا�سحة. غري تنا�سلية واأع�ساء ال�سفن، كي�س يف البول جمرى وفتحة البلوغ، مبا يف ذلك خ�سونة ال�سوت، وت�سخم الع�سو الذكري، وفرط ت�سبغ ال�سفن وزيادة كتلة الع�سالت. الكلمات املفتاحية: XY،46 ا�سطرابات النمو اجلن�سية؛ الت�ستو�ستريون 5-األفا-ريدوكتا�س؛ ديهدروت�ستو�سرتون؛ فتحة جمرى البول يف كي�س ال�سفن؛ بلوغ؛ تقرير حالة؛ اململكة العربية ال�سعودية. Late Diagnosis of 5-α-Reductase Type 2 Deficiency in an Adolescent Girl with Primary Amenorrhoea Case report Abdul-Rahman A. Hummadi,1 Ayel O. Yahya,1 *Awad M. Al-Qahtani2 Sultan Qaboos University Med J, May 2017, Vol. 17, Iss. 2, pp. e218–220, Epub. 20 Jun 17 Submitted 23 Oct 16 Revision Req. 14 Nov 16; Revision Recd. 11 Dec 16 Accepted 15 Jan 17 case report doi: 10.18295/squmj.2016.17.02.014 Case Report An 18-year-old patient was referred to an endocrine clinic in Jizan, Saudi Arabia, in April 2014 with primary amenorrhoea, virilisation and a lack of secondary sex characteristics. As female external genitalia were present at birth, she had been raised as female. The patient reported vocal changes over the course of two years, which made her voice sound deeper and harsher. Additionally, over the previous year, she had experienced unusually thick hair growth on her upper and lower limbs as well as the axillary and inguinal regions. Her previous developmental history was normal. There was no history of consanguinity on the part of the parents. The 5-α-reductase enzyme, also known as 3-oxo-5α-steroid 4-dehydrogenase, converts testosterone to the more physiologically active dihydrotestosterone (DHT).1 A deficiency of 5-α- reductase results in a rare autosomal recessive 46,XY disorder of sexual development caused by mutations in the steroid 5-α-reductase 2 (SRD5A2) gene located on chromosome 2p23.1,2 Most affected individuals have female external genitalia present at birth and are raised as female; however, a few patients are adequately masculinised by childbirth and are raised as male.2,3 Due to its rarity, the prevalence of 5-α-reductase type 2 deficiency in the general population is unknown.4 Abdul-Rahman A. Hummadi, Ayel O. Yahya and Awad M. Al-Qahtani Case Report | e219 On physical examination, the patient communicated well, appeared to be comfortable and was not in any emotional distress. Her height was 162 cm, she weighed 68 kg and her body mass index was 25.9 kg/m2. Hair was present on the extensor surfaces of her forearms and legs. Breast development corresponded to Tanner stage I, while pubic hair growth was categ- orised as Tanner stage III. Further physical examin- ation revealed pseudovaginal perineoscrotal hypo- spadias and a blind vaginal pouch. The scrotal skin was rugose and pigmented with the right gonad palpable in the inguinal ligament. The left gonad was 3.2 cm and located in the labioscrotal pouch, while the phallus was 3 cm in length. The results of a hormonal assay are shown in Table 1. Magnetic resonance imaging of the pelvis revealed no uterine or ovarian tissue. A scrotal sac was apparent and contained the left testis which measured 33 x 24 x 23 mm and was of normal shape and signal intensity [Figure 1A]. The undescended right testis was located in the right inguinal canal measuring 31 x 24 x 20 mm and was also of normal shape and signal intensity [Figure 1B]. The urinary bladder, urethra and seminal vesicles appeared normal. No prostatic tissue was identified. A final diagnosis was made of a 46,XY disorder of sexual development due to 5-α-reductase type 2 deficiency. After extensive counselling with the patient and her parents, the patient decided to undergo gender reassignment to become male. Discussion At birth, clinical symptoms of 5-α-reductase type 2 deficiency range from the appearance of female external genitalia to a nearly complete male phenotype; however, most patients who present with ambiguous genitalia are usually diagnosed in early infancy.5 The current case describes the late diagnosis of 5-α-reductase type 2 deficiency in an 18-year-old female patient presenting with primary amenorrhoea and characteristics of virilisation. Young children with 5-α-reductase type 2 deficiency can either escape diagnosis or be misdiagnosed as having partial or complete androgen insensitivity syndrome.6 Since biochemical findings can be misleading, molecular testing is mandatory to identify the underlying cause of a disorder of sexual development.6,7 However, measurement of the basal serum concentration and the testosterone/DHT ratio after puberty is usually sufficient for an accurate Figure 1: Magnetic resonance imaging (MRI) of the pelvis of an 18-year-old female patient with primary amenorrhoea, virilisation and a lack of secondary sex characteristics showing (A) no uterine or ovarian tissue and the presence of a scrotal sac (asterisk) containing a left testis of normal shape and signal intensity (arrow) and (B) an undescended right testis (arrow) in the right inguinal canal of normal shape and signal intensity. Table 1: Hormonal assay results of an 18-year-old female patient with primary amenorrhoea, virilisation and a lack of secondary sex characteristics Hormone Result Normal range Males Females FSH in mIU/mL 6 2–12 2–12 LH in mIU/mL 7 2–12 2–12 Cortisol in µg/dL 7.2 5.1–19.9 5.1–19.9 Estradiol in pg/mL 42.22 7.6–40.9 12.5–163.5 T in ng/dL 572 200–1,080 10–70 DHT in ng/dL 8 29–76 22–380 DHEA in μg/dL 126 22–640 22–380 AE in ng/dL 127 ≤250 ≤250 T/DHT ratio 67.8 8–16 8–16 17-OHP in ng/mL 0.8 0.1–1.4 0.1–2.9 FSH = follicle-stimulating hormone; LH = luteinising hormone; T = testosterone; DHT = dihydrotestosterone; DHEA = dehydro- epiandrosterone; AE = androstenedione; OHP = hydroxyprogestrone. Late Diagnosis of 5-α-Reductase Type 2 Deficiency in an Adolescent Girl with Primary Amenorrhoea Case report e220 | SQU Medical Journal, May 2017, Volume 17, Issue 2 References 1. Fratianni CM, Imperato-McGinley J. The syndrome of 5[alpha]- reductase deficiency. Endocrinologist 1994; 4:302–14. 2. Genetics Home Reference. 5-alpha reductase deficiency. From: https://ghr.nlm.nih.gov/condition/5-alpha-reductase-defi ciency Accessed: Dec 2016. 3. Hekimsoy Z, Hatipoglu O, Öz D, Alarslan P, Özmen B. 5-Alpha reductase type 2 deficiency: A case report. Endocr Abstr 2012; 29:P418. 4. Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocr Rev 1993; 14:577–93. doi: 10.1210/er.14. 5.577. 5. Bertelloni S, Scaramuzzo RT, Parrini D, Baldinotti F, Tumini S, Ghirri P. Early diagnosis of 5alpha-reductase deficiency in newborns. Sex Dev 2007; 1:147–51. doi: 10.1159/000102103. 6. Walter KN, Kienzle FB, Frankenschmidt A, Hiort O, Wudy SA, van der Werf-Grohmann N, et al. Difficulties in diagnosis and treatment of 5alpha-reductase type 2 deficiency in a newborn with 46,XY DSD. Horm Res Paediatr 2010; 74:67–71. doi: 10.1159/000313372. 7. Skordis N, Neocleous V, Kyriakou A, Efstathiou E, Sertedaki A, Philibert P, et al. The IVS1-2A>G mutation in the SRD5A2 gene predominates in Cypriot patients with 5α reductase deficiency. J Endocrinol Invest 2010; 33:810–14. doi: 10.3275/7079. 8. Maleki N, Kalantar Hormozi M, Iranparvar Alamdari M, Tavosi Z. 5-alpha-reductase 2 deficiency in a woman with primary amenorrhea. Case Rep Endocrinol 2013; 2013:631060. doi: 10.1155/2013/631060. 9. Mendonca BB, Inacio M, Costa EM, Arnhold IJ, Silva FA, Nicolau W, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency: Diagnosis, psychological eval- uation, and management. Medicine (Baltimore) 1996; 75:64–76. doi: 10.1097/00005792-199603000-00003. 10. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 1974; 186:1213–15. doi: 10.1126/science.186.4170.1213. 11. Sinnecker GH, Hiort O, Dibbelt L, Albers N, Dörr HG, Hauss H, et al. Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Am J Med Genet 1996; 63:223–30. doi: 10.1002/(SICI)1096-8628(19960 503)63:1<223::AID-AJMG39>3.0.CO;2-O. 12. Conte FA, Grumbach MM. Abnormalities of sexual determination and differentiation. In: Greenspan FS, Gardner DG. Basic & Clinical Endocrinology, 7th ed. New York, USA: McGraw-Hill Medical, 2003. Pp. 564–607. diagnosis of 5-α-reductase type 2 deficiency.8 In the present case, the diagnosis of 5-α-reductase 2 type 2 deficiency was based on the patient’s clinical presentation and a hormonal assay which revealed an abnormally elevated testosterone/DHT ratio of >60. Nevertheless, karyotyping and molecular studies are recommended to confirm a homozygous mutation of the SRD5A2 gene; unfortunately, this could not be performed in the current case.4,7 Many 46,XY individuals raised as females will experience psychological difficulties during puberty, which results in most affected patients choosing to undergo gender reassignment to become male, as in the present case.9–11 In such cases, either DHT or high- dose testosterone therapy should be initiated so as to increase the size of the phallus. For patients diagnosed after infancy and whose gender identity is definitively female, a genitoplasty, prophylactic orchiectomy and oestrogen substitution therapy are recommended.12 Conclusion Although rare, 5-α-reductase type 2 deficiency should be suspected among female patients presenting with pubertal virilisation and primary amenorrhoea. Early recognition of this condition is critical to avoid psychological distress on the part of the patient, particularly after puberty. Molecular analysis of the SRD5A2 gene should be performed to confirm the diagnosis. https://doi.org/10.1210/er.14.5.577 https://doi.org/10.1210/er.14.5.577 https://doi.org/10.1159/000102103 https://doi.org/10.1159/000313372 https://doi.org/10.3275/7079 https://doi.org/10.1155/2013/631060 https://doi.org/10.1097/00005792-199603000-00003 https://doi.org/10.1126/science.186.4170.1213 https://doi.org/10.1002/%28SICI%291096-8628%2819960503%2963:1%3C223::AID-AJMG39%3E3.0.CO%3B2-O https://doi.org/10.1002/%28SICI%291096-8628%2819960503%2963:1%3C223::AID-AJMG39%3E3.0.CO%3B2-O